APA (7th ed.) Citation

M, L., JS, S., OE, R., FS, H., SD, Z., & S, G. (2020). Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer, 126(23), 5088. https://doi.org/10.1002/cncr.33165

Chicago Style (17th ed.) Citation

M, Li, Sack JS, Rahma OE, Hodi FS, Zucker SD, and Grover S. "Outcomes After Resumption of Immune Checkpoint Inhibitor Therapy After High-grade Immune-mediated Hepatitis." Cancer 126, no. 23 (2020): 5088. https://doi.org/10.1002/cncr.33165.

MLA (9th ed.) Citation

M, Li, et al. "Outcomes After Resumption of Immune Checkpoint Inhibitor Therapy After High-grade Immune-mediated Hepatitis." Cancer, vol. 126, no. 23, 2020, p. 5088, https://doi.org/10.1002/cncr.33165.